{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:14:11Z","timestamp":1788383651428,"version":"build-2803163510"},"reference-count":28,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Providence","doi-asserted-by":"publisher","award":["ZR2023QH336"],"award-info":[{"award-number":["ZR2023QH336"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015642","name":"Shandong Higher Education Young Science and Technology Support Program","doi-asserted-by":"publisher","award":["2023KJ224"],"award-info":[{"award-number":["2023KJ224"]}],"id":[{"id":"10.13039\/501100015642","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Program of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202312382"],"award-info":[{"award-number":["tsqn202312382"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Papillary thyroid carcinoma (PTC) is the most common malignant thyroid cancer. Several clinicopathological features may affect therapeutic efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To analyze the relationship between thyroglobulin antibodies (TgAb) with clinicopathological features and efficacy of 131I ablation in PTC patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 548 PTC patients who underwent total thyroidectomy and subsequent 131I ablation were enrolled. The clinicopathological features between TgAb-positive and TgAb-negative groups were compared. The clinicopathological characteristics and risk factors affecting the efficacy of 131I ablation were analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 157 cases (28.65%) were in the preoperative TgAb-positive group and 391 cases (71.35%) were in the TgAb-negative group. The TgAb-positive group was younger and had a higher proportion of females, anti-thyroid peroxidase antibody (TPOAb) positivity, multiple foci, coexistence of PTC, Hashimoto thyroiditis, and increased TSH; they had reduced FT4 and FT3, and reduced BRAF positivity (all P &amp;lt; .05). Logistic regression analysis showed positive correlation between TgAb positivity and multifocality (P &amp;lt; .05). Compared with the noneffective group (88 cases, 16.06%), the effective group (460 cases, 84.94%) had a reduced proportion of TgAb positivity and multifocality, a shorter time interval between surgery and subsequent 131I ablation, and a lower proportion of initial 131I ablation dosage &amp;gt; 100 mCi (all P &amp;lt; .05). Logistic regression showed that TgAb positivity, longer time interval between surgery and subsequent 131I ablation, and initial 131I ablation dosage &amp;gt; 100 mCi were positively correlated with nonefficacy of 131I ablation (odds ratios 2.248, 1.012, and 3.128, respectively; P &amp;lt; .05).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>TgAb positivity is associated with increased risk of multiple foci and unfavorable efficacy of 131I ablation in PTC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae898","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:35:42Z","timestamp":1738928142000},"page":"e3245-e3251","source":"Crossref","is-referenced-by-count":1,"title":["Correlation of TgAb With Clinicopathological Features and Unfavorable Efficacy of 131I Ablation in PTC"],"prefix":"10.1210","volume":"110","author":[{"given":"Xiang","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]},{"name":"Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Pingdu People's Hospital , Qingdao 266700 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2446-0725","authenticated-orcid":false,"given":"Bingzi","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodi","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]},{"name":"Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College , Beijing 100730 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6597-420X","authenticated-orcid":false,"given":"Yangang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6668-1570","authenticated-orcid":false,"given":"Kun","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Echocardiography, The Affiliated Hospital of Qingdao University , Qingdao 266003 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"issue":"5","key":"2025091917014737300_dgae898-B1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/thy.2021.0662","article-title":"Thyroid cancer incidence and mortality trends in the United States: 2000-2018","volume":"32","author":"Megwalu","year":"2022","journal-title":"Thyroid"},{"issue":"7","key":"2025091917014737300_dgae898-B2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1089\/1050725041517057","article-title":"Why measure thyroglobulin autoantibodies rather than thyroid peroxidase autoantibodies?","volume":"14","author":"McLachlan","year":"2004","journal-title":"Thyroid"},{"issue":"5","key":"2025091917014737300_dgae898-B3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.beem.2013.07.003","article-title":"Thyroglobulin antibody (TgAb) methods- strengths, pitfalls and clinical utility for monitoring TgAb-positive patients with differentiated thyroid cancer","volume":"27","author":"Spencer","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"12","key":"2025091917014737300_dgae898-B4","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1210\/jc.2011-1740","article-title":"Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC)","volume":"96","author":"Spencer","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025091917014737300_dgae898-B5","first-page":"234","article-title":"Positive thyroid antibodies and risk of thyroid cancer: a systematic review and meta-analysis","volume":"11","author":"Xiao","year":"2019","journal-title":"Mol Clin Oncol"},{"issue":"8","key":"2025091917014737300_dgae898-B6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.2009.0384","article-title":"Thyroglobulin antibody is associated with increased cancer risk in thyroid nodules","volume":"20","author":"Kim","year":"2010","journal-title":"Thyroid"},{"issue":"8","key":"2025091917014737300_dgae898-B7","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1245\/s10434-014-3593-x","article-title":"Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma","volume":"21","author":"Vasileiadis","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"2025091917014737300_dgae898-B8","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.amjsurg.2015.12.030","article-title":"Thyroglobulin antibodies as a potential predictive marker of papillary thyroid carcinoma in patients with indeterminate cytology","volume":"212","author":"Karatzas","year":"2016","journal-title":"Am J Surg"},{"issue":"7","key":"2025091917014737300_dgae898-B9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1089\/thy.2013.0698","article-title":"Clinical aggressiveness and long-term outcome in patients with papillary thyroid cancer and circulating antithyroglobulin autoantibodies","volume":"24","author":"Durante","year":"2014","journal-title":"Thyroid"},{"issue":"57","key":"2025091917014737300_dgae898-B10","doi-asserted-by":"crossref","first-page":"97407","DOI":"10.18632\/oncotarget.22129","article-title":"Unfavorable efficacy to 131I ablation in BRAFV600E mutant papillary thyroid carcinoma with positive tg-ab","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"2025091917014737300_dgae898-B11","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1089\/thy.2019.0368","article-title":"Investigating antithyroglobulin antibody as a prognostic marker for differentiated thyroid cancer: a meta-analysis and systematic review","volume":"30","author":"Lee","year":"2020","journal-title":"Thyroid"},{"issue":"4","key":"2025091917014737300_dgae898-B12","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eprac.2020.10.017","article-title":"Positive thyroid peroxidase antibody and thyroglobulin antibody are associated with better clinicopathologic features of papillary thyroid cancer","volume":"27","author":"Li","year":"2021","journal-title":"Endocr Pract"},{"issue":"1","key":"2025091917014737300_dgae898-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"4","key":"2025091917014737300_dgae898-B14","first-page":"287","article-title":"The new (version 9) American joint committee on cancer tumor, node, metastasis staging for cervical cancer","volume":"71","author":"Olawaiye","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2025091917014737300_dgae898-B15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4158\/EP10123.OR","article-title":"Autoimmune thyroid disease: a risk factor for thyroid cancer","volume":"17","author":"Azizi","year":"2011","journal-title":"Endocr Pract"},{"key":"2025091917014737300_dgae898-B16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3389\/fendo.2020.00452","article-title":"Clinical analysis of preoperative anti-thyroglobulin antibody in papillary thyroid cancer between 2011 and 2015 in Beijing, China: a retrospective study","volume":"11","author":"Jia","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025091917014737300_dgae898-B17","doi-asserted-by":"crossref","first-page":"648670","DOI":"10.1155\/2015\/648670","article-title":"High thyroglobulin antibody levels increase the risk of differentiated thyroid carcinoma","volume":"2015","author":"Qin","year":"2015","journal-title":"Dis Markers"},{"issue":"4","key":"2025091917014737300_dgae898-B18","doi-asserted-by":"crossref","first-page":"950","DOI":"10.21037\/gs-20-445","article-title":"Correlation between thyroid auto\u2043antibodies and the risk of thyroid papillary carcinoma","volume":"9","author":"Peng","year":"2020","journal-title":"Gland Surg"},{"issue":"9","key":"2025091917014737300_dgae898-B19","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00268-021-06185-2","article-title":"Multifocality and progression of papillary thyroid microcarcinoma during active surveillance","volume":"45","author":"Nagaoka","year":"2021","journal-title":"World J Surg"},{"issue":"5","key":"2025091917014737300_dgae898-B20","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14639\/0392-100X-1709","article-title":"Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients","volume":"37","author":"Liang","year":"2017","journal-title":"Acta Otorhinolaryngol Ital"},{"issue":"17","key":"2025091917014737300_dgae898-B21","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.3390\/cancers14174287","article-title":"The immune landscape of papillary thyroid cancer in the context of autoimmune thyroiditis","volume":"14","author":"Pani","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2025091917014737300_dgae898-B22","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/cancers13061292","article-title":"Targeting BCL-2 in cancer: advances, challenges, and perspectives","volume":"13","author":"Hafezi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2025091917014737300_dgae898-B23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s12020-013-0121-x","article-title":"Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer","volume":"46","author":"Wu","year":"2014","journal-title":"Endocrine"},{"issue":"1","key":"2025091917014737300_dgae898-B24","doi-asserted-by":"crossref","first-page":"e004049","DOI":"10.1136\/jitc-2021-004049","article-title":"TSH-TSHR axis promotes tumor immune evasion","volume":"10","author":"Wu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"2025091917014737300_dgae898-B25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1530\/ERC-14-0258","article-title":"Association of Hashimoto's thyroiditis with thyroid cancer","volume":"21","author":"Azizi","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"23","key":"2025091917014737300_dgae898-B26","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1158\/1078-0432.CCR-14-0879","article-title":"MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro","volume":"20","author":"Angell","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025091917014737300_dgae898-B27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1210\/er.2001-0029","article-title":"The sodium\/iodide symporter (NIS): characterization, regulation, and medical significance","volume":"24","author":"Doh\u00e1n","year":"2003","journal-title":"Endocr Rev"},{"key":"2025091917014737300_dgae898-B28","doi-asserted-by":"crossref","first-page":"1222470","DOI":"10.3389\/fendo.2023.1222470","article-title":"Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study","volume":"14","author":"Han","year":"2023","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae898\/61792624\/dgae898.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/10\/e3245\/61792624\/dgae898.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/10\/e3245\/61792624\/dgae898.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:01:59Z","timestamp":1758315719000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/10\/e3245\/8005189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae898","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,2,7]]}}}